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Abstract
The mechanisms governing the epidemiology dynamics and success determinants of a specific healthcare-associated
methicillin-resistant S. aureus (HA-MRSA) clone in hospital settings are still unclear. Important epidemiological changes have
occurred in Europe since 2000 that have been related to the appearance of the ST22-IV clone. Between 2006 and 2010, we
observed the establishment of the ST22-IV clone displacing the predominant Italian clone, ST228-I, in a large Italian
university hospital. To investigate the factors associated with a successful spread of epidemic MRSA clones we studied the
biofilm production, the competitive behavior in co-culture, the capacity of invasion of the A549 cells, and the susceptibility
to infection in a murine model of acute pneumonia of the two major HA-MRSA clones, ST22-IV and ST228-I. We showed that
persistence of ST22-IV is associated with its increased biofilm production and capacity to inhibit the growth of ST228-I in co-
culture. Compared to ST228-I, ST22-IV had a significantly higher capacity to invade the A549 cells and a higher virulence in a
murine model of acute lung infection causing severe inflammation and determining death in all the mice within 60 hours.
On the contrary, ST228-I was associated with mice survival and clearance of the infection. ST22-IV, compared with ST228-I,
caused a higher number of persistent, long lasting bacteremia. These data suggest that ST22-IV could have exploited its
capacity to i) increase its biofilm production over time, ii) maintain its growth kinetics in the presence of a competitor and
iii) be particularly invasive and virulent both in vitro and in vivo, to replace other well-established MRSA clones, becoming
the predominant European clone.
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Introduction
Infections caused by antibiotic-resistant strains of Staphylococcus
aureus have risen to epidemic proportions globally [1]. The overall
burden of disease caused by methicillin-resistant S. aureus (MRSA)
strains has reached alarming rates in many countries in both
healthcare and community settings [2–4].
MRSA, for its ability to become resistant to virtually all
antimicrobial agents available, to survive in hostile environments
and to adapt to new ecological niches poses a major challenge to
Infection Control Programs. After successfully spreading to
hospitals and healthcare settings worldwide (HA-MRSA, health-
care-associated MRSA), two decades ago MRSA emerged in the
community (CA-MRSA, community-acquired MRSA), causing
infection in healthy people without predisposing risk factors for
HA-MRSA infection. CA- and HA-MRSA strains can be
distinguished for their genetic background, phenotype and
virulence factors. CA-MRSA strains are susceptible to most non
b-lactams antibiotics, and contain smaller, more mobile SCCmec
allotypes, SCCmec IV, V and VII, and virulence factors genes,
such as those coding for the Panton Valentine leucocydin (PVL),
which is responsible, in combination with other exotoxins, for their
enhanced pathogenicity. Since 2003, MRSA has been isolated
from livestock and humans exposed to infected animals in several
countries, revealing the zoonotic potential of MRSA. Such MRSA
has been dubbed livestock-associated methicillin-resistant Staphy-
lococcus aureus (LA-MRSA) [5,6]. Interactions between these
different reservoirs have been reported, including nosocomial
infections by CA-MRSA [7,8] and LA-MRSA [9,10].
Epidemiological studies using several molecular typing methods
have shown that few highly epidemic MRSA (EMRSA) clones
cause the majority of HA-MRSA infections worldwide. These
EMRSA clones emerged upon acquisition of the SCCmec element
by successful methicillin susceptible S. aureus clones, belonging to
five phylogenetically distinct clonal complexes (CC): CC5
(sequence type ST5-I, -II, -IV, -VI), CC8 (ST247-I, ST239-III,
ST8-IV), CC22 (ST22-IV), CC30 (ST36-II) and CC45 (ST45-II, -
IV) [11,12].
Since 2000, important epidemiological changes have occurred
in Europe: the frequency of multidrug resistant (MDR) MRSA
clones gradually decreased while the frequency of other epidemic
clones still sensitive to non b-lactams, such as ST22-IV (EMRSA-
15), increased [13–19].
A recent study, that traced the dynamic changes of HA-MRSA
lineages in Italy, showed that over a 17-year period MDR-MRSA
clones ST247-I/IA and ST239-III were replaced by ST228-I
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(South German), ST8-IV (EMRSA-2/26) and ST22-IV [20].
Using pulsed-field gel electrophoresis and SCCmec typing, we
characterized 575 clinically relevant, non-duplicated MRSA
strains (499 index cases and 76 secondary cases due to nosocomial
transmission), isolated from 2006 to 2010 at the San Raffaele
hospital (hSR), a large private university hospital located in Milan.
We identified three main epidemic HA-MRSA clones: ST22-IV
(33,3% of isolates, considering only the index cases), ST228-I
(26%) and ST8-IV (15,8%). During the 5-year study period,
ST22-IV became the predominant clone in hSR, replacing the
most prevalent Italian clone, ST228-I. Similar shifts have been
observed in several European countries [15–18,21].
The mechanisms involved in the selection of pandemic MRSA
clones in nosocomial settings have not yet been clarified. In order
to investigate the factors associated with the successful establish-
ment and spread of an epidemic MRSA clone, as well as with the
phenomenon of clone displacement in hospital environments, we
studied both in vitro and in vivo virulence properties of the two
major HA-MRSA clones, ST22-IV and ST228-I. In particular, we
evaluated their ability to produce biofilm, their in vitro competitive
behavior in co-culture and their capacity to invade the A549 cell
line, as well as the virulence in a murine model of acute
pneumonia.
Results
Biofilm Production
Selected MRSA strains belonging to both epidemic (ST228-I,
ST22-IV, ST8-IV) and sporadic (ST5-II, ST239-III, ST1-IV,
ST8-IV USA300) clones were tested for their capacity to produce
biofilm in vitro (see Materials and Methods).
As shown in Figure 1, the sporadic MRSA clones ST5-II, ST1-
IV and ST8-IV USA300 were associated with low biofilm
production, the exception being ST239-III Brazilian clone that
was classified as a moderate biofilm producer. Accordingly, the
variants of epidemic clones isolated sporadically were weak
producers and their incidence decreased rapidly during the study
period (data not shown). On the contrary, the predominant
variants of clones ST228-I, ST22-IV and ST8-IV were associated
with high biofilm production. Interestingly, the clone ST22-IV
significantly increased its biofilm production during the study
period (p,0,01, Figure 1). In particular, the two predominant
variants of the clone ST22-IV, A and B, presented opposite
isolation trends, with variant A increasing from 22,2% in 2006 to
36,5% in 2010 and variant B decreasing from 44,4% to 30,7%,
and, while the variant B remained a weak biofilm producer, the
variant A significantly increased its biofilm production from weak
to moderate (p,0,05, data not shown).
In vitro Competition Experiments
The epidemic clones ST228-I and ST22-IV have different
genetic background (respectively CC5 and CC22), SCCmec type (I
and IV) and resistance phenotype (gentamicin-resistant and
susceptible). In order to determine if the epidemiological changes
can be ascribed to different growth kinetics and/or competitive
behavior, we evaluated their growth rate in pure culture and in co-
culture. We selected two pairs of strains belonging to the variants
B5 (strains 67, isolated in 2006, and 442, isolated in 2009) and A
(strains 54, isolated in 2006, and 459, isolated in 2009) of the
clones ST228-I and ST22-IV respectively: during the 5-year
period, while the variant B5 exhibited a decreasing isolation trend,
the variant A was detected with increasing frequency.
Figure 2 shows the growth kinetics and the competition indexes
(CI) for mixed culture of one pair of strains; similar results were
obtained with the second pair of strains. As shown in Figure 2, the
two clones presented similar growth kinetics in pure culture; in co-
culture, while the variant A of the clone ST22-IV maintained the
growth rate observed in pure culture, the growth of the variant B5
of the clone ST228-I was significantly inhibited by the presence of
ST22-IV, as confirmed by the CI.
Invasion in A549 Cell Line Model
To investigate the virulence properties of the clones ST22-IV
and ST228-I, we used a well-characterized in vitro model, the
epithelial cell line A549. In particular, we evaluated the invasion
capacity of the major variants of the epidemic clones ST22-IV
(variants A and B) and ST228-I (variants B2 and B5) (Table 1).
Both MRSA clones were able to invade the epithelial cells A549
but at different efficiency (Figure 3). The percentages of invasion
associated with the variants A and B of the clone ST22-IV (48,3%
and 31% respectively) were significantly higher compared to the
ones associated with the variants B5 and B2 of the clone ST228-I
(16,5% and 17,1% respectively; ST22-IV A vs. ST228-I B5:
p,0,001; ST22-IV A vs. ST228-I B2: p,0,05; ST22-IV B vs.
ST228-I B5: p,0,05; ST22-IV B vs. ST228-I B2: p,0,05).
Virulence in a Mouse Model of Acute Lung Infection
To test differences in virulence between the MRSA clones
ST22-IV and ST228-I, we used a murine model of acute
pneumonia. Variant A of the clone ST22-IV (strain 54) and
variant B5 of the clone ST228-I (strain 67) were used to infect
C57Bl/6NCrl mice. Lethality was assessed after intratracheal
challenge with 5*108 cfu/lung of each strain.
As shown in Figure 4, the two MRSA clones determined
opposite outcomes: the ST22-IV strain was fully lethal within 60
hours from infection, while the ST228-I strain was attenuated and
all mice survived for at least one week after challenge (ST22-IV
(variant A) vs. ST228-I (variant B5): p,0,001).
Bacterial load was then determined in the lungs and spleen of
the infected mice (Figure 5). Moribund mice infected with ST22-
IV presented a significantly higher bacterial load in the lungs
(median value 8,5*108 cfu per lung) compared with mice infected
with ST228-I and sacrificed at day 3 (median value 4*104 cfu,
p,0,05). Complete clearance of ST228-I strain was observed
when the infection was prolonged for 7 days. The bacterial load in
the spleen was higher in mice of the ST22-IV group (median
2*104 cfu) and lower in ST228-I group (median 140 cfu), although
not statistically significant.
To assess clinical strain-specific traits of acute pneumonia, lung
histopathology was performed on mice challenged with different
MRSA clones (Figure 6). The lungs of mice infected with the
ST22-IV clone presented a heavily damaged structure and
noteworthy inflammatory infiltrate, while the lungs of mice
infected with the ST228-I clone and able to clear the infection
presented large areas where the normal pulmonary parenchyma
was preserved.
Genes Coding for Virulence Factors
The MRSA strains used for the competitive growth cultures and
for the experiments in the mouse model (strains 54 and 67
belonging to ST22-IV and ST228-I respectively) were character-
ized for the presence of genes encoding for virulence factors. Both
clones shared genes encoding for enterotoxins (sei, sea, sem, seg, seo),
for factors associated to tissue invasion (hla, hld, psm-a), for the
clumping factor B (clfB), and for the capsular polysaccharide type 5
(cap5). The variant B5 of the clone ST228-I also carried genes
encoding for other adhesins (fnbA, efb, ebpS) and for an additional
factor of cellular lysis (luk E). The variant A of the clone ST22-IV
Epidemic MRSA Clones Virulence
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Figure 1. Biofilm production of the main sporadic and epidemic MRSA clones identified in hSR. Panel A: sporadic MRSA clones; panel B:
epidemic MRSA clones. The dotted line indicates the threshold separating moderate and strong biofilm producers from non-producers and weak
producers with Biofilm Unit (BU) value ,0,46. Each symbol represents a single strain. For each clone the average BU value is indicated by the black
bar. Three to eleven MRSA strains for sporadic clones and thirty-three to sixty-five MRSA strains for epidemic clones were tested. All MRSA strains
tested originated from clinically significant samples (see Materials and Methods). For each epidemic clone (B) the biofilm production is reported for
2006–2007 and 2008–2009 for comparison purposes. Statistically significant differences are indicated by symbols when present: ** indicates a p value
,0,01.
doi:10.1371/journal.pone.0043153.g001
Epidemic MRSA Clones Virulence
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harbored additional genes encoding for an enterotoxin (sen) and for
two other toxins (hlb, hlg) (Table S1).
Clinical Data
Between 2009 and 2010 we identified and analyzed 16 cases of
persistent infection caused by MRSA strains belonging to one of
the predominant variants of the clones ST22-IV and ST228-I. As
shown in Figure 7 and Table 2, 9 and 7 patients had a second
MRSA isolate belonging to the ST22-IV and to the ST228-I clone
respectively. The median of days between the first and the last
MRSA detection for the clone ST228-I was 40 days, while for the
ST22-IV was 55 days.
The average age of patients with persistent infection caused by
the clone ST228-I and ST22-IV was 60,5 years and 59,7 years
Figure 2. In vitro competitive growth cultures. The MRSA clones ST22-IV (variant A, strain 54 isolated from sputum) and ST228-I (variant B5,
strain 67 isolated from blood) were grown in pure culture (A) and in co-culture after inoculation in BHI broth at equal ratio (B and C). Growth rate was
monitored for 24 hours by colony count after plating and normalizing the output value obtained at each time (t) to the input value at time 0 (t0).
CFU: colony forming unit; statistically significant differences are indicated by symbols when present: * indicates a p value ,0,05; **: p,0,01; ***:
p,0,001. The competition index for mixed culture (D) was calculated at the different time points as the ST22-IV/ST228-I CFU ratio for the output (time
t) divided by the corresponding ratio for the input (inoculum at time t = 0).
doi:10.1371/journal.pone.0043153.g002
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respectively. Cases of resolving MRSA bacteremia, defined as an
initial blood culture that yielded MRSA and subsequent blood
cultures negative for MRSA after antibiotic treatment, were
equally caused by both ST22-IV and ST228-I clones (data not
shown). On the contrary, cases of persistent MRSA bacteremia
were significantly associated to ST22-IV clone (ST22-IV vs.
ST228-I: p,0,001): four out of nine patients (44,4%) infected by
the ST22-IV clone had persistent bacteremia, whose median
length was 67,5 days, while only one (14,2%) of the seven patients
infected by the ST228-I clone had persistent bacteremia that
lasted 15 days (Table 2). ST228-I clone in the remaining 85,8% of
the cases caused infections of the respiratory tract.
Discussion
The mechanisms and factors governing the epidemiological
dynamics and determining the establishment and successful
spreading of a HA-MRSA clone in hospital settings are still
unclear. Until the end of the 1990s, the international scenario was
dominated by multidrug resistant (MDR) epidemic MRSA clones,
suggesting a central role for multidrug resistance in the selection of
successful MRSA clones, especially in the hospital environment
where the selective antibiotic pressure is notoriously high. Since
2000, however, important epidemiological changes have occurred
and classical MDR MRSA clones have been replaced by more
susceptible clones. In Europe, these changes have been related to
the gentamicin-susceptible ST22-IV clone, otherwise known as
EMRSA-15, which has shown a particular ability to substitute
other predominant clones in several countries, such as France,
United Kingdom, Portugal, Spain, Hungary and Germany [16-
19,21].
In line with the epidemiological changes observed in Europe in
the last decade, in our institution during the five-year period 2006–
2010, we detected the establishment of the ST22-IV clone that
displaced the predominant Italian clone ST228-I. We investigated
both in vitro and in vivo virulence properties associated with this
phenomenon of clone replacement in hospital settings.
Table 1. Epidemic MRSA clones identified during the study period 2006–2010.
Frequency of isolation of the clone
MRSA clone (%)a 2006 2007 2008 2009 2010 Major variants of the clone (%)b
ST22-IV (33,3%) 20,4% 26,5% 35% 36,7% 38,8% A (28%); B (25%); C (7%)
ST228-I (26%) 31,8% 33,6% 29,8% 22,7% 20,9% B2 (16%); B5 (13%); B1 (8%)
ST8-IV (15,8%) 6,8% 16,3% 21,6% 17,2% 17,8% A1 (23%); A2 (22%); B (21%); C (11%)
aPercent of MRSA strains belonging to each clone, considering only the index cases (n = 499);
bpercent of MRSA strains belonging to the major variants of each epidemic clone identified (n = 166 for ST22-IV; n = 131 for ST228-I; n = 80 for ST8-IV).
doi:10.1371/journal.pone.0043153.t001
Figure 3. Percentage of invasion of A549 cell line by MRSA clones ST22-IV and ST228-I. Three to six different strains for each predominant
variant of the two clones (ST22-IV variants A and B, ST228-I variants B2 and B5) were tested. For ST22-IV strains tested originated from lower
respiratory tract (LRT, 37%), pus (37%) and blood (26%); for ST228-I strains tested were isolated from LRT (55%) and blood (45%). The percentage of
invasion was determined by plating cellular lysates after 2 hours contact between bacteria and cells’ monolayer, followed by 1 hour treatment with
lysostaphin to kill extracellular bacteria. Each symbol represents a single strain; the black bar indicates the average percentage of invasion. Statistically
significant differences are indicated by symbols when present: * indicates a p value ,0,05; ***: p,0,001.
doi:10.1371/journal.pone.0043153.g003
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Figure 4. Survival curves of mice infected with MRSA clones ST228-I (variant B5) and ST22-IV (variant A). C57Bl/6NCrl mice were
infected intratracheally with 5*108 cfu per mouse of either the variant B5 of the clone ST228-I (strain 67, squares) or the variant A of the clone ST22-IV
(strain 54, circles). Two to three independent experiments were pooled (n: 10 mice per MRSA strain). Statistical analysis of pairwise comparison is
indicated (Mantel-Cox test): *** indicates a p value ,0,001.
doi:10.1371/journal.pone.0043153.g004
Figure 5. Bacterial load in lung and spleen of mice infected with MRSA clones ST228-I and ST22-IV. C57Bl/6NCrl mice were infected
intratracheally with 5*108 cfu per mouse of either the variant B5 of the clone ST228-I (strain 67, squares) or the variant A of the clone ST22-IV (strain
54, circles). Moribund mice infected with ST22-IV clone (n = 5) were sacrificed between 6 and 60 hours from infection; surviving mice infected with
ST228-I clone (n = 5) were sacrificed at 72 hours from infection. Each animal is represented by a different color; the black bar indicates the median cfu
per organ. Statistically significant differences are indicated by symbols when present: * indicates a p value ,0,05.
doi:10.1371/journal.pone.0043153.g005
Epidemic MRSA Clones Virulence
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We found a correlation between the successful establishment
and persistence in nosocomial settings of MRSA clones and their
capacity to produce biofilm, so far demonstrated only for the
epidemic Brazilian clone [22]. We also detected the ability of the
predominant variant A of the clone ST22-IV to favorably modify
its phenotype, thus acquiring a selective advantage over the
variant B, a weak biofilm producer associated with a decreasing
isolation trend over time. Biofilm constitutes a protective mode of
growth that confers to bacteria resistance to antibiotic therapy and
host immune response, thus probably increasing their persistence
in the host, as well as in the environment and inanimate surfaces,
and their pathogenic potential [23].
The role played by genetic background in establishing the
success of a specific MRSA clone is unclear. Laurent et al.
described a correlation between gentamicin susceptibility and the
increased capacity of MRSA clones to replicate, establish and
spread in nosocomial environments, compared with gentamicin-
resistant clones [19]. Both ST22-IV and ST228-I clones presented
similar in vitro growth kinetics when grown in pure culture, but
different behavior in competitive culture as well as different
virulence properties. In co-culture, the clone ST22-IV maintained
an unaltered growth rate and was able to significantly inhibit the
growth of the competitor clone ST228-I.
MRSA infections are often persistent and associated with a slow
response to antibiotic therapy as well as with recurrences, and a
consequent extended duration of antimicrobial therapy and
hospital stay. S. aureus has classically been considered as an
extracellular pathogen. Conversely, there is growing evidence
suggesting the ability of S. aureus to internalize and survive in
different cell types [24]. Intracellular presence of bacteria may
explain the poor response to antibiotics and the development of
chronic infections [25]. We noticed a significantly higher capacity
of the clone ST22-IV to invade the human alveolar epithelial cells
A549 compared to the clone ST228-I, that could enable this clone
to elude both the host immune response and the effects of
antimicrobial agents, and to cause persistent or recurrent
Figure 6. Histopathology in murine lung infected with MRSA clones ST22-IV (variant A) and ST228-I (variant B5). C57Bl/6NCrl were
infected intratracheally with 5*108 cfu per mouse of either the variant A of the clone ST22-IV (strain 54) or the variant B5 of the clone ST228-I (strain
67). Mice were sacrificed between 3 and 7 days from infection with ST22-IV (left panel) and ST228-I (right panel), respectively. Lungs were removed en
bloc, fixed in 4% paraformaldehyde/PBS and processed for paraffin embedding. Longitudinal sections were stained with hematoxylin and eosin.
Upper panel: 2,56magnification; lower panel: 106magnification.
doi:10.1371/journal.pone.0043153.g006
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infections. The analysis of sequential MRSA strains, isolated from
patients with persistent MRSA infection, identified 16 patients
with multiple isolates genotypically indistinguishable from the first
(same pulsotype, spa-type and sequence type) and belonging to one
of the predominant variants of the clones ST22-IV and ST228-I.
ST22-IV, compared with ST228-I, was able to cause a signifi-
cantly higher percentage of persistent, long lasting bacteremia
(44,4% vs. 14,2%, respectively), despite the presence of antimi-
crobial therapy. On the contrary, ST228-I clone in 85,8% of the
cases determined infections of the respiratory tract. Further in vitro
and in vivo studies that aim to evaluate the ability of these clones to
persist intracellularly could confirm this data.
Considering that pneumonia caused by MRSA accounts for 20–
40% of nosocomial infections and it is still one of the leading
causes of death during flu epidemics [26], and considering that
more than 35% of our MRSA strains have been isolated from
clinically significant respiratory samples obtained from infected
patients, we further evaluated the in vivo virulence associated with
the MRSA clones ST22-IV and ST228-I using a murine model of
acute lung infection. Mice challenged with either the ST22-IV or
the ST228-I clone showed opposite clinical outcomes. The clone
ST22-IV presented a higher virulence compared to clone ST228-
I: it seriously damaged the lung, compromising its structure and
causing severe inflammation, thus entering the bloodstream and
determining sepsis and death in all the mice within 60 hours. This
data correlated with the noteworthy in vitro invasion capacity
associated with this clone. On the contrary, the reduced virulence
of the clone ST228-I was associated with the survival of all animals
and the clearance of the infection.
The analysis of the pathotypes associated with the two clones
revealed that, while ST228-I presented a major number of genes
encoding for adhesins (fnbA, efb, ebpS), ST22-IV presented a major
number of toxins (hlb, hlg), whose role is still unclear, although they
probably contribute to its higher capacity to invade observed both
in vitro and in vivo. Giese et al. have recently shown synergistic
activity between the d-toxin (hld) and the b-toxin (hlb) that allows S.
aureus to escape from the phago-endosomes of human epithelial
and endothelial cells, thus avoiding degradation [27]. It is not clear
if the escape from the phago-endosome leads to the subsequent
host cell’s death or if it allows bacteria to survive in the cytosol.
The data reported here suggest that the EMRSA clone ST22-
IV could have exploited its capacity to i) increase its biofilm
production over time, ii) maintain its growth kinetics in the
presence of a competitor clone and iii) be particularly invasive and
virulent both in vitro and in vivo, so as to replace other well-
established EMRSA clones and become the predominant Euro-
pean clone. Furthermore, the ability of the clone ST22-IV to
determine a higher number of persistent, long lasting bacteremia
compared to ST228-I, revealed an additional factor that could
help to explain its epidemiological success. In fact, although MDR
clones have been progressively replaced by more susceptible
clones, the treatment of MRSA infections is increasingly
problematic: growing evidence suggests the ability of this pathogen
to survive intracellularly, even for prolonged time periods, in the
cytoplasm of both phagocytic and non-phagocytic cells [24,28]. It
is presumable that intracellular persistence is a bacterial strategy to
subvert immunological defense mechanisms, as well as extracel-
lular bactericidal concentrations of antibiotics. An intracellular
niche might then serve as a reservoir for chronic or relapsing
infections and/or contribute to chronic carriage of the pathogen
and to its spreading in both hospital settings and the community.
Further studies using both in vitro and in vivo models of persistent
infection could help to elucidate if these mechanisms of adaptation
and persistence are also present in clinical EMRSA clones that we
characterized for acute virulence.
Materials and Methods
Ethics Statement
Animal studies were conducted according to protocols approved
by the San Raffaele Scientific Institute (Milan, Italy) Institutional
Animal Care and Use Committee (IACUC) and adhered strictly to
Figure 7. Persistent infections caused by epidemic MRSA clones ST228-I and ST22-IV. Each symbol represents the last MRSA strains
isolated from subsequent clinical samples obtained from patients with a previous MRSA isolation. The black bar indicates the median of the days
between the first and the last detection of the same MRSA strain.
doi:10.1371/journal.pone.0043153.g007
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the Italian Ministry of Health guidelines for the use and care of
experimental animals.
Bacterial Strains
A total of 575 MRSA non-duplicated strains (499 index cases
and 76 secondary cases due to nosocomial transmission), isolated
from 2006 to 2010 from hospitalized patients with severe MRSA
infection, were included in the study. The strains were isolated
from clinical samples originating from lower respiratory tract
(LRT, 36,6%), blood (27%), pus (15,8%), biopsy (9,1%) and other
sites (11,5%). All these strains were characterized by pulsed-field
gel electrophoresis and SCCmec typing, which allowed identifying
epidemic and sporadic MRSA clones. Epidemic clones were
constantly detected during the whole study period and their
frequency of isolation was .5% (Table 1); on the contrary,
sporadic clones were rarely detected with a frequency of isolation
,5%. Each epidemic clone presented major and minor variants
(or sub-clones) associated to different pulsotypes that were detected
at a frequency .5% and ,5% respectively.
DNA Extraction and PCR for Virulence Factors Genes
Bacterial DNA was prepared from isolated colonies suspended
in 100 ml Triton X-100 lysis buffer with 1% Triton and 50 mg/ml
lysostaphin, incubated at 37uC for 15 min, heated at 95uC for
15 min. After centrifugation, 5 ml of the supernatant was used for
PCR. Selected virulence factors were detected by PCR using
primers and protocol described by Diep BA et al. [29].
Biofilm Production
Quantitative determination of biofilm production was per-
formed in a microtiter plate under static conditions following the
procedure previously described by Stepanovic S et al. [30], and
using SH1000 as positive control and TSB as negative control.
The biofilm units (BU) were calculated using the formula:
ODbiofilm/ODgrowth. Classification: BU#0.230 non-producers,
BU.0.230 and #0.460 weak producers, BU.0.460 and
#0.920 moderate producers, BU.0.920 strong producers. Each
MRSA strain was tested in triplicate and each experiment was
repeated three times independently. For ST228-I clone the isolates
tested belonged to major variants B1, B2 and B5 and originated
from blood (64%), LTR (30%) and pus (6%) (Table 1). For ST22-
IV and ST8-IV clones isolates tested belonged to variants A, B, C
and A1, A2, B, C respectively and originated from blood (42%),
LRT (32%), pus (13%) and biopsy (13%). For ST5-NY/Japan
clone strains originated from LRT (45%), blood (20%), pus
(17,5%) and biopsy (17,5%); for ST239-Brazilian clone strains
originated from blood (42%), LRT (42%) and pus (16%); for ST1
clone isolates originated from pus (66,6%) and LRT (33,3%); ST8-
USA300 and ST8-USA300-related, being community-acquired
MRSA clones, caused mainly skin and soft tissue infections (SSTI)
and 62% of isolates tested for biofilm production originated from
pus, 25% from LRT and 13% from blood. Figure 1 reports the
average BU value for each MRSA strain tested.
Competitive Growth Experiments
Two MRSA isolates belonging to each of the ST22-IV and
ST228-I clones were tested against each other in both pure and
mixed cultures for competitive growth. Each pair of strains were
inoculated at equal ratio (1 OD600, optical density) from mid-
exponential phase pure cultures in a final volume of 30 ml of
Tryptic Soy Broth and incubated at 37uC with agitation (180 rpm)
for 24 hours. Growth rates of pure and mixed cultures were
monitored every 2 hours up until 8 hours and at 24 hours, by
dilution plating on Tryptic Soy agar (TSA) plates with or without
gentamicin (32 mg/mL), to discriminate the two MRSA clones,
and CFU count. Each experiment was repeated three times
independently. The competition index (CI) for mixed culture was
calculated as the ST22-IV/ST228-I CFU ratio for the output
(obtained at the different time points) divided by the corresponding
ratio for the input (inoculum at time t = 0) [31].
Invasion Assay
Bacterial invasion was investigated using the A549 cell line as
previously described by Liang X et al [32]. A549 cell line (ATCC
number CCL-185) was obtained from LGC Standards. Briefly,
26105 cells were seeded on 24-well flat-bottom plates and
incubated for 2 hours at 37uC with 1–26106 bacteria from the
mid-exponential phase; adherent and extracellular bacteria were
killed by lysostaphin treatment (20mg/ml) for 1 hour at 37uC; after
washing wells and treating with Trypsin-EDTA, followed by
Triton X-100 0,025% to detach and lyse cells, internalized
bacteria were serially diluted and plated on TSA for counting.
Each MRSA strain was tested in duplicate and each experiment
was repeated three times independently. Figure 3 reports the
average percentage of invasion for each MRSA strain tested.
Mouse Model of Acute Lung Infection
C57Bl/6NCrl mice (20–22 gr) were purchased by Charles
River. Mice were housed in filtered cages under specific-pathogen
conditions and permitted unlimited access to food and water. Prior
to animal experiments, the clinical MRSA strains were grown for
3 h to reach exponential phase. Next, the bacteria were pelleted by
centrifugation (2700 g, 15 min), washed twice with sterile PBS and
the OD of the bacterial suspension was adjusted by spectropho-
tometry at 600 nm. The intended number of cfu was extrapolated
from a standard growth curve [33,34]. Appropriate dilutions with
sterile PBS were made to prepare the inoculum of 56108 cfu per
mouse. Mice were anesthetized with 375 mg/kg Avertin (2,2,2-
tribromoethanol, 97%; Aldrich), the trachea directly visualized by
a ventral midline incision, exposed and intubated with a sterile,
flexible 22-g cannula attached to a 1 ml syringe according to
established procedures [35,36]. Mice were monitored for mortality
and sacrificed by CO2 administration up to 7 days. To determine
the bacterial load murine lungs and spleens were aseptically
excised, homogenized, and plated onto TSA agar with or without
gentamicin (32 mg/mL).
Histological Examination
Moribund mice were sacrificed by CO2 administration while
surviving mice were sacrificed after 7 days from infection, lungs
were removed en bloc and fixed in 4% paraformaldehyde/PBS, at
4uC for 24 h, and processed for paraffin embedding. Longitudinal
2-mm sections taken at regular intervals were obtained using a
microtome from the proximal, medial and distal lung regions.
Sections were stained with Haematoxylin-Eosin according to
standard procedures and examined blindly.
Statistical Analysis
Data were analyzed with the software GraphPad Prism 5. Data
concerning biofilm production, competitive cultures and invasion
were analyzed using two-tailed non-parametric Student’s t test.
For in vivo experiments survival data were analyzed with the Log
Rank test (Mantel-Cox). Value of p,0,05 was considered to be
statistically significant.
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Table S1 Virulence characteristics of the MRSA strains used for
in vivo experiments.
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